Dr. Torsten Mummenbrauer is a seasoned biotech entrepreneur with more than 25 years of experience in the biotech and pharmaceutical industry, from seed financing to IPO on the Nasdaq. Before joining iDEL Therapeutics as Chief Business Officer, he was CEO at ExeVir in Gent, Belgium and Velvio in Regensburg, Germany. From 2016 to 2019, he was SVP Business Development at Hookipa Pharma in Vienna, Austria, and from 2015 to 2016, he was Senior Director Business Development at MorphoSys AG in Munich, Germany.

From 2004 to 2015, Torsten held various positions at GSK Vaccines in Rixensart, Belgium. He started as Associated Director of Business Development, initially supporting the emerging diseases team, and later the bacterial vaccines team and the oncology immunotherapy team. Between 2005 and 2010, Torsten led all commercial activities in the area of pandemic influenza at GSK. In recent years, he led the Business Development team at GSK Vaccines.

Before joining GSK Vaccines, Torsten was Patent and Licensing Manager at Garching Innovation, now Max Planck Innovation at the Max Planck Society in Munich, Germany. Torsten has negotiated and closed more than 150 transactions, ranging from in-licensing and out-licensing to acquisitions.

Torsten holds a degree in molecular biology from the University of Cologne and a doctorate (Ph.D.) with a focus on tumor virology from the Heinrich Pette Institute at the University Hospital Eppendorf in Hamburg, Germany.